Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target.
Identifieur interne : 001D36 ( Main/Exploration ); précédent : 001D35; suivant : 001D37Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target.
Auteurs : Young-Sam Keum [Corée du Sud] ; Yong-Joo JeongSource :
- Biochemical pharmacology [ 1873-2968 ] ; 2012.
Descripteurs français
- KwdFr :
- ADN viral (), ADN viral (métabolisme), Antiviraux (), Antiviraux (pharmacologie), Apigénine (), Apigénine (pharmacologie), Flavonoïdes (), Flavonoïdes (pharmacologie), Helicase (), Helicase (antagonistes et inhibiteurs), Helicase (métabolisme), Humains, Hydrolyse, Methyltransferases (), Methyltransferases (antagonistes et inhibiteurs), Methyltransferases (métabolisme), Nucleoside-triphosphatase (), Nucleoside-triphosphatase (antagonistes et inhibiteurs), Nucleoside-triphosphatase (métabolisme), Syndrome respiratoire aigu sévère (traitement médicamenteux), Virus du SRAS (), Virus du SRAS (enzymologie).
- MESH :
- antagonistes et inhibiteurs : Helicase, Methyltransferases, Nucleoside-triphosphatase.
- enzymologie : Virus du SRAS.
- métabolisme : ADN viral, Helicase, Methyltransferases, Nucleoside-triphosphatase.
- pharmacologie : Antiviraux, Apigénine, Flavonoïdes.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- ADN viral, Antiviraux, Apigénine, Flavonoïdes, Helicase, Humains, Hydrolyse, Methyltransferases, Nucleoside-triphosphatase, Virus du SRAS.
English descriptors
- KwdEn :
- Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Apigenin (chemistry), Apigenin (pharmacology), DNA Helicases (antagonists & inhibitors), DNA Helicases (chemistry), DNA Helicases (metabolism), DNA, Viral (chemistry), DNA, Viral (metabolism), Flavonoids (chemistry), Flavonoids (pharmacology), Humans, Hydrolysis, Methyltransferases (antagonists & inhibitors), Methyltransferases (chemistry), Methyltransferases (metabolism), Nucleoside-Triphosphatase (antagonists & inhibitors), Nucleoside-Triphosphatase (chemistry), Nucleoside-Triphosphatase (metabolism), SARS Virus (drug effects), SARS Virus (enzymology), Severe Acute Respiratory Syndrome (drug therapy).
- MESH :
- chemical , antagonists & inhibitors : DNA Helicases, Methyltransferases, Nucleoside-Triphosphatase.
- chemical , chemistry : Antiviral Agents, Apigenin, DNA Helicases, DNA, Viral, Flavonoids, Methyltransferases, Nucleoside-Triphosphatase.
- chemical , metabolism : DNA Helicases, DNA, Viral, Methyltransferases, Nucleoside-Triphosphatase.
- chemical , pharmacology : Antiviral Agents, Apigenin, Flavonoids.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- enzymology : SARS Virus.
- Humans, Hydrolysis.
Abstract
Severe acute respiratory syndrome (SARS) was the first pandemic in the 21st century to claim more than 700 lives worldwide. However, effective anti-SARS vaccines or medications are currently unavailable despite being desperately needed to adequately prepare for a possible SARS outbreak. SARS is caused by a novel coronavirus, and one of its components, a viral helicase, is emerging as a promising target for the development of chemical SARS inhibitors. In the following review, we describe the characterization, family classification, and kinetic movement mechanisms of the SARS coronavirus (SCV) helicase-nsP13. We also discuss the recent progress in the identification of novel chemical inhibitors of nsP13 in the context of our recent discovery of the strong inhibition of the SARS helicase by natural flavonoids, myricetin and scutellarein. These compounds will serve as important resources for the future development of anti-SARS medications.
DOI: 10.1016/j.bcp.2012.08.012
PubMed: 22935448
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001311
- to stream PubMed, to step Curation: 001311
- to stream PubMed, to step Checkpoint: 001363
- to stream Ncbi, to step Merge: 002557
- to stream Ncbi, to step Curation: 002557
- to stream Ncbi, to step Checkpoint: 002557
- to stream Main, to step Merge: 001D59
- to stream Main, to step Curation: 001D36
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target.</title><author><name sortKey="Keum, Young Sam" sort="Keum, Young Sam" uniqKey="Keum Y" first="Young-Sam" last="Keum">Young-Sam Keum</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Dongguk University, Goyang, Gyeonggi-do, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy, Dongguk University, Goyang, Gyeonggi-do</wicri:regionArea><wicri:noRegion>Gyeonggi-do</wicri:noRegion></affiliation></author><author><name sortKey="Jeong, Yong Joo" sort="Jeong, Yong Joo" uniqKey="Jeong Y" first="Yong-Joo" last="Jeong">Yong-Joo Jeong</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22935448</idno><idno type="pmid">22935448</idno><idno type="doi">10.1016/j.bcp.2012.08.012</idno><idno type="wicri:Area/PubMed/Corpus">001311</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001311</idno><idno type="wicri:Area/PubMed/Curation">001311</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001311</idno><idno type="wicri:Area/PubMed/Checkpoint">001363</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001363</idno><idno type="wicri:Area/Ncbi/Merge">002557</idno><idno type="wicri:Area/Ncbi/Curation">002557</idno><idno type="wicri:Area/Ncbi/Checkpoint">002557</idno><idno type="wicri:Area/Main/Merge">001D59</idno><idno type="wicri:Area/Main/Curation">001D36</idno><idno type="wicri:Area/Main/Exploration">001D36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target.</title><author><name sortKey="Keum, Young Sam" sort="Keum, Young Sam" uniqKey="Keum Y" first="Young-Sam" last="Keum">Young-Sam Keum</name><affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Dongguk University, Goyang, Gyeonggi-do, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>College of Pharmacy, Dongguk University, Goyang, Gyeonggi-do</wicri:regionArea><wicri:noRegion>Gyeonggi-do</wicri:noRegion></affiliation></author><author><name sortKey="Jeong, Yong Joo" sort="Jeong, Yong Joo" uniqKey="Jeong Y" first="Yong-Joo" last="Jeong">Yong-Joo Jeong</name></author></analytic><series><title level="j">Biochemical pharmacology</title><idno type="eISSN">1873-2968</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (pharmacology)</term><term>Apigenin (chemistry)</term><term>Apigenin (pharmacology)</term><term>DNA Helicases (antagonists & inhibitors)</term><term>DNA Helicases (chemistry)</term><term>DNA Helicases (metabolism)</term><term>DNA, Viral (chemistry)</term><term>DNA, Viral (metabolism)</term><term>Flavonoids (chemistry)</term><term>Flavonoids (pharmacology)</term><term>Humans</term><term>Hydrolysis</term><term>Methyltransferases (antagonists & inhibitors)</term><term>Methyltransferases (chemistry)</term><term>Methyltransferases (metabolism)</term><term>Nucleoside-Triphosphatase (antagonists & inhibitors)</term><term>Nucleoside-Triphosphatase (chemistry)</term><term>Nucleoside-Triphosphatase (metabolism)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (enzymology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral ()</term><term>ADN viral (métabolisme)</term><term>Antiviraux ()</term><term>Antiviraux (pharmacologie)</term><term>Apigénine ()</term><term>Apigénine (pharmacologie)</term><term>Flavonoïdes ()</term><term>Flavonoïdes (pharmacologie)</term><term>Helicase ()</term><term>Helicase (antagonistes et inhibiteurs)</term><term>Helicase (métabolisme)</term><term>Humains</term><term>Hydrolyse</term><term>Methyltransferases ()</term><term>Methyltransferases (antagonistes et inhibiteurs)</term><term>Methyltransferases (métabolisme)</term><term>Nucleoside-triphosphatase ()</term><term>Nucleoside-triphosphatase (antagonistes et inhibiteurs)</term><term>Nucleoside-triphosphatase (métabolisme)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (enzymologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>DNA Helicases</term><term>Methyltransferases</term><term>Nucleoside-Triphosphatase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term><term>Apigenin</term><term>DNA Helicases</term><term>DNA, Viral</term><term>Flavonoids</term><term>Methyltransferases</term><term>Nucleoside-Triphosphatase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>DNA Helicases</term><term>DNA, Viral</term><term>Methyltransferases</term><term>Nucleoside-Triphosphatase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Apigenin</term><term>Flavonoids</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Helicase</term><term>Methyltransferases</term><term>Nucleoside-triphosphatase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ADN viral</term><term>Helicase</term><term>Methyltransferases</term><term>Nucleoside-triphosphatase</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Apigénine</term><term>Flavonoïdes</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Hydrolysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>ADN viral</term><term>Antiviraux</term><term>Apigénine</term><term>Flavonoïdes</term><term>Helicase</term><term>Humains</term><term>Hydrolyse</term><term>Methyltransferases</term><term>Nucleoside-triphosphatase</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) was the first pandemic in the 21st century to claim more than 700 lives worldwide. However, effective anti-SARS vaccines or medications are currently unavailable despite being desperately needed to adequately prepare for a possible SARS outbreak. SARS is caused by a novel coronavirus, and one of its components, a viral helicase, is emerging as a promising target for the development of chemical SARS inhibitors. In the following review, we describe the characterization, family classification, and kinetic movement mechanisms of the SARS coronavirus (SCV) helicase-nsP13. We also discuss the recent progress in the identification of novel chemical inhibitors of nsP13 in the context of our recent discovery of the strong inhibition of the SARS helicase by natural flavonoids, myricetin and scutellarein. These compounds will serve as important resources for the future development of anti-SARS medications.</div></front></TEI><affiliations><list><country><li>Corée du Sud</li></country></list><tree><noCountry><name sortKey="Jeong, Yong Joo" sort="Jeong, Yong Joo" uniqKey="Jeong Y" first="Yong-Joo" last="Jeong">Yong-Joo Jeong</name></noCountry><country name="Corée du Sud"><noRegion><name sortKey="Keum, Young Sam" sort="Keum, Young Sam" uniqKey="Keum Y" first="Young-Sam" last="Keum">Young-Sam Keum</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22935448
|texte= Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22935448" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |